A translational study of Galectin-3 as an early biomarker and potential therapeutic target for ischemic-reperfusion induced acute kidney injury - ScienceDirect
We evaluated Galectin-3 (Gal-3) as a potential early biomarker of acute kidney disease (AKI), and the effect of Gal-3 inhibition by modified citrus pe…
A translational study of Galectin-3 as an early biomarker and potential therapeutic target for ischemic-reperfusion induced acute kidney injury - ScienceDirect
We evaluated Galectin-3 (Gal-3) as a potential early biomarker of acute kidney disease (AKI), and the effect of Gal-3 inhibition by modified citrus pe…
Dipyridamole is a drug in use for the past 55 years for treating heart conditions. In 2012 a breakthrough was reached when Moshe Rogosnitzky discovered that dipyridamole eye drops are effective in treating difficult eye conditions such as dry eye, pterygium, pinguecula, cataract, nevus and a variety of other eye disorders.
The fecal microbiome of ALS patients - Neurobiology of Aging
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative motor neuron disease accompanied by both systemic and central nervous system–specific…
Small peptides attack ovarian cancer on two fronts, research shows Psa
Two forms of a peptide derived from a naturally-occurring human protein can force tumors to shrink significantly in an animal model of metastatic ovarian cancer, according to a team of researchers.
Small peptides attack ovarian cancer on two fronts, research shows Psa
Two forms of a peptide derived from a naturally-occurring human protein can force tumors to shrink significantly in an animal model of metastatic ovarian cancer, according to a team of researchers.
Small peptides attack ovarian cancer on two fronts, research shows Psa
Two forms of a peptide derived from a naturally-occurring human protein can force tumors to shrink significantly in an animal model of metastatic ovarian cancer, according to a team of researchers.
Small peptides attack ovarian cancer on two fronts, research shows Psa
Two forms of a peptide derived from a naturally-occurring human protein can force tumors to shrink significantly in an animal model of metastatic ovarian cancer, according to a team of researchers.
Small peptides attack ovarian cancer on two fronts, research shows Psa
Two forms of a peptide derived from a naturally-occurring human protein can force tumors to shrink significantly in an animal model of metastatic ovarian cancer, according to a team of researchers.
Small peptides attack ovarian cancer on two fronts, research shows Psa
Two forms of a peptide derived from a naturally-occurring human protein can force tumors to shrink significantly in an animal model of metastatic ovarian cancer, according to a team of researchers.